Novo Nordisk A/S-Product Pipeline Review-2015

Novo Nordisk A/S-Product Pipeline Review-2015

  • Products Id :- GMDHC07256CDB
  • |
  • Pages: 93
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Novo Nordisk A/S-Product Pipeline Review-2015


Global Markets Direct's, 'Novo Nordisk A/S-Product Pipeline Review-2015', provides an overview of the Novo Nordisk A/S's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Novo Nordisk A/S's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


The report provides brief overview of Novo Nordisk A/S including business description, key information and facts, and its locations and subsidiaries

The report reviews current pipeline of Novo Nordisk A/S's human therapeutic division and enlists all their major and minor projects

The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones

Special feature on out-licensed and partnered product portfolio

The report summarizes all the dormant and discontinued pipeline projects

Latest company statement

Latest news and deals relating to the Novo Nordisk A/S's pipeline products

Reasons To Buy

Evaluate Novo Nordisk A/S's strategic position with total access to detailed information on its product pipeline

Assess the growth potential of Novo Nordisk A/S in its therapy areas of focus

Identify new drug targets and therapeutic classes in the Novo Nordisk A/S's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas

Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps

Develop strategic initiatives by understanding the focus areas of Novo Nordisk A/S and exploit collaboration and partnership opportunities

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Plan mergers and acquisitions effectively by identifying the most promising pipeline of Novo Nordisk A/S

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Explore the dormant and discontinued projects of Novo Nordisk A/S and identify potential opportunities in those areas

Avoid Intellectual Property Rights related issues

Read More

Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications


Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 6

Novo Nordisk A/S Snapshot 7

Novo Nordisk A/S Overview 7

Key Information 7

Key Facts 7

Novo Nordisk A/S-Research and Development Overview 8

Key Therapeutic Areas 8

Novo Nordisk A/S-Pipeline Review 11

Pipeline Products by Stage of Development 11

Pipeline Products-Monotherapy 12

Pipeline Products-Combination Treatment Modalities 13

Pipeline Products-Partnered Products 14

Partnered Products/Combination Treatment Modalities 15

Novo Nordisk A/S-Pipeline Products Glance 16

Novo Nordisk A/S-Late Stage Pipeline Products 16

Pre-Registration Products/Combination Treatment Modalities 16

Phase III Products/Combination Treatment Modalities 17

Novo Nordisk A/S-Clinical Stage Pipeline Products 18

Phase II Products/Combination Treatment Modalities 18

Phase I Products/Combination Treatment Modalities 19

Novo Nordisk A/S-Early Stage Pipeline Products 20

Preclinical Products/Combination Treatment Modalities 20

Discovery Products/Combination Treatment Modalities 21

Novo Nordisk A/S-Drug Profiles 22

(insulin degludec + insulin aspart) 22

Product Description 22

Mechanism of Action 22

R&D Progress 22

(insulin degludec + liraglutide) 24

Product Description 24

Mechanism of Action 24

R&D Progress 24

insulin degludec 26

Product Description 26

Mechanism of Action 26

R&D Progress 26

liraglutide (recombinant) 29

Product Description 29

Mechanism of Action 29

R&D Progress 29

NN-1218 32

Product Description 32

Mechanism of Action 32

R&D Progress 32

NN-9535 34

Product Description 34

Mechanism of Action 34

R&D Progress 34

nonacog beta pegol 36

Product Description 36

Mechanism of Action 36

R&D Progress 36

somatropin 38

Product Description 38

Mechanism of Action 38

R&D Progress 38

turoctocog alfa pegol 39

Product Description 39

Mechanism of Action 39

R&D Progress 39

NN-8828 41

Product Description 41

Mechanism of Action 41

R&D Progress 41

OG-217SC 43

Product Description 43

Mechanism of Action 43

R&D Progress 43

OI-338GT 45

Product Description 45

Mechanism of Action 45

R&D Progress 45

Oral Insulin 46

Product Description 46

Mechanism of Action 46

R&D Progress 46

concizumab 48

Product Description 48

Mechanism of Action 48

R&D Progress 48

G-530L 49

Product Description 49

Mechanism of Action 49

R&D Progress 49

LAI-287 50

Product Description 50

Mechanism of Action 50

R&D Progress 50

LAI-338 51

Product Description 51

Mechanism of Action 51

R&D Progress 51

NN-1957 52

Product Description 52

Mechanism of Action 52

R&D Progress 52

NNC-01740833 53

Product Description 53

Mechanism of Action 53

R&D Progress 53

OG-987GT 54

Product Description 54

Mechanism of Action 54

R&D Progress 54

OG-987SC 55

Product Description 55

Mechanism of Action 55

R&D Progress 55

semaglutide 56

Product Description 56

Mechanism of Action 56

R&D Progress 56

Immunotherapy for Type 1 Diabetes 57

Product Description 57

Mechanism of Action 57

R&D Progress 57

Novo Nordisk A/S-Pipeline Analysis 58

Novo Nordisk A/S-Pipeline Products by Target 58

Novo Nordisk A/S-Pipeline Products by Route of Administration 59

Novo Nordisk A/S-Pipeline Products by Molecule Type 60

Novo Nordisk A/S-Pipeline Products by Mechanism of Action 61

Novo Nordisk A/S-Recent Pipeline Updates 62

Novo Nordisk A/S-Dormant Projects 80

Novo Nordisk A/S-Discontinued Pipeline Products 81

Discontinued Pipeline Product Profiles 81

balaglitazone 81

coagulation factor XIII A-subunit (recombinant) 81

NN-1952 82

NN-1954 82

NN-1955 82

NN-1956 82

NN-1998 82

NN-7128 82

NN-7129 82

NN-8555 82

NN-8828 83

NN-9112 83

NN-9161 83

NN-9925 83

NNC126-0083 83

OG-217GT 83

ragaglitazar 83

tifenazoxide 83

vatreptacog alfa (activated) 83

Novo Nordisk A/S-Company Statement 84

Novo Nordisk A/S-Locations And Subsidiaries 86

Head Office 86

Other Locations & Subsidiaries 86

Appendix 92

Methodology 92

Coverage 92

Secondary Research 92

Primary Research 92

Expert Panel Validation 92

Contact Us 92

Disclaimer 93

List of Tables

Novo Nordisk A/S, Key Information 7

Novo Nordisk A/S, Key Facts 7

Novo Nordisk A/S-Pipeline by Indication, 2015 9

Novo Nordisk A/S-Pipeline by Stage of Development, 2015 11

Novo Nordisk A/S-Monotherapy Products in Pipeline, 2015 12

Novo Nordisk A/S-Combination Treatment Modalities in Pipeline, 2015 13

Novo Nordisk A/S-Partnered Products in Pipeline, 2015 14

Novo Nordisk A/S-Partnered Products/ Combination Treatment Modalities, 2015 15

Novo Nordisk A/S-Pre-Registration, 2015 16

Novo Nordisk A/S-Phase III, 2015 17

Novo Nordisk A/S-Phase II, 2015 18

Novo Nordisk A/S-Phase I, 2015 19

Novo Nordisk A/S-Preclinical, 2015 20

Novo Nordisk A/S-Discovery, 2015 21

Novo Nordisk A/S-Pipeline by Target, 2015 58

Novo Nordisk A/S-Pipeline by Route of Administration, 2015 59

Novo Nordisk A/S-Pipeline by Molecule Type, 2015 60

Novo Nordisk A/S-Pipeline Products by Mechanism of Action, 2015 61

Novo Nordisk A/S-Recent Pipeline Updates, 2015 62

Novo Nordisk A/S-Dormant Developmental Projects,2015 80

Novo Nordisk A/S-Discontinued Pipeline Products, 2015 81

Novo Nordisk A/S, Subsidiaries 86

List of Figures

Novo Nordisk A/S-Pipeline by Top 10 Indication, 2015 9

Novo Nordisk A/S-Pipeline by Stage of Development, 2015 11

Novo Nordisk A/S-Monotherapy Products in Pipeline, 2015 12

Novo Nordisk A/S-Partnered Products in Pipeline, 2015 14

Novo Nordisk A/S-Pipeline by Top 10 Target, 2015 58

Novo Nordisk A/S-Pipeline by Top 10 Route of Administration, 2015 59

Novo Nordisk A/S-Pipeline by Top 10 Molecule Type, 2015 60

Novo Nordisk A/S-Pipeline Products by Top 10 Mechanism of Action, 2015 61

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@]

Current R&D Portfolio of Novo Nordisk A/S; Novo Nordisk A/S - Key Therapeutics; Novo Nordisk A/S - Pipeline Overview and Promising Molecules; Novo Nordisk A/S - News; Novo Nordisk A/S - Latest Updates; Novo Nordisk A/S - Pipeline; Novo Nordisk A/S - Discontinued/Dormant Projects

select a license

Single User License
USD 1500 INR 101175
Site License
USD 3000 INR 202350
Corporate User License
USD 4500 INR 303525



An excellent provider. Thorough, precise and outstanding insight. They drill down to what we need and their reports are effective at integrating text with supporting graphics and charts. Their reports are a great resource to go back too. ...

Coherent, high-quality, thoroughly-researched reports. We received a very quick response to all our queries which eventually expedited the entire process....

Well structured, the insights they shared with us were very helpful and reliable. Their timely assistance make their services invaluable to us. I would highly recommend them and would definitely use them again in the future if needed...

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

Related Products in vertical
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India


Company Brochure

Engage with Us

sales [@]